gptkbp:instanceOf
|
gptkb:chemical_compound
investigational drug
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
|
gptkbp:ATCCode
|
L01EE39
|
gptkbp:brand
|
gptkb:Cotellic
|
gptkbp:CASNumber
|
934660-93-2
|
gptkbp:combines
|
gptkb:vemurafenib
|
gptkbp:developedBy
|
gptkb:Exelixis
gptkb:Genentech
|
gptkbp:hasMolecularFormula
|
C21H20F3N5O2
|
gptkbp:hasSMILES
|
CC(C)(O)N1CCN(CC1)C(=O)C2=CC(=C(C=C2F)NC3=CC(=C(C=C3)F)I)F
|
gptkbp:hasUNII
|
Q1ZXA2J1XK
|
https://www.w3.org/2000/01/rdf-schema#label
|
GDC-0973
|
gptkbp:IUPACName
|
(S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][4-(2-hydroxypropan-2-yl)piperazin-1-yl]methanone
|
gptkbp:KEGGID
|
D10541
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:mechanismOfAction
|
MEK inhibitor
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1743088
25102825
28536941
DB09020
|
gptkbp:routeOfAdministration
|
oral
|
gptkbp:sideEffect
|
nausea
diarrhea
fatigue
rash
photosensitivity
|
gptkbp:synonym
|
gptkb:cobimetinib
|
gptkbp:target
|
gptkb:MEK1
gptkb:MEK2
|
gptkbp:usedFor
|
melanoma
|
gptkbp:bfsParent
|
gptkb:Cotellic
|
gptkbp:bfsLayer
|
7
|